Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Date:5/12/2008

weeks for a total of 6 doses. All patients will have active RA while on methotrexate. The trial is expected to enroll 70 patients at multiple sites in Europe. The primary endpoint of the study is the ACR20 response, a composite endpoint that indicates a 20% improvement in RA signs and symptoms, at 12 weeks.

Medarex also announced that results from the MDX-1100 Phase 1 trials will be presented at the Digestive Disease Week (DDW) meeting, being held May 17 - 22, 2008 in San Diego. The following abstracts are expected to be the subject of presentations at the DDW 2008 conference:

-- "A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and

Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal

Antibody, in Healthy Subjects" (Abstract #T1145) - Poster presentation

on May 20, 2008 from 12:00 to 2:00 PM CDT.

-- "A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of MDX-1100,

a High-Affinity, Neutralizing, Fully Human IgG1k Anti-CXCL10 (IP10)

Monoclonal Antibody, in Ulcerative Colitis" (Abstract #704) - Oral

presentation on May 20, 2008 from 3:00 to 3:15 PM CDT.

-- "CXCL10 Expression and Biological Activities in Inflammatory Bowel

Disease" (Abstract #W1170) - Poster presentation on May 21, 2008 from

12:00 to 2:00 PM CDT.

These presentations support the development of MDX-1100 for the treatment of inflammatory diseases such as ulcerative colitis and rheumatoid arthritis.

About MDX-1100

MDX-1100 is a fully human antibody that targets CXCL10 (also known as IP-10), a chemokine expressed in association with multiple inflammatory disease indications such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

About Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colon and is characterized by inflammation and ulceration of the lining of the colon. Sy
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 6, 2015 Nihon University is pleased ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up with ... in Tokyo, Japan . Many ... research will present their achievements and future prospects ... industry produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... 4, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) , ... en ligne , Prendre en charge l,hypertension ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24 /CNW/ - The weight loss medication Xenical,(orlistat ... such as blood pressure, glycaemic,control and lipid profile ... and hypertension, according to a study analysis,presented at ... ,This analysis strengthens the wealth of data already ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled “ ... the time they turn age 35 a quarter of all women in the U.S. will suffer ... loss is stigmatized and rarely discussed. One woman, a former beauty queen, who was ...
(Date:7/6/2015)... ... July 06, 2015 , ... The Asian-Pacific market for rheumatoid ... is expected to grow at a CAGR of over 3.2 percent in the years ... is likely to be mainly spurred by an anticipated launch of a number of ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope ... patients, caregivers and medical professionals to chat with the CHN patient services team ... “Receiving a cancer diagnosis is often the most traumatic experience of a person’s ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... Florida (PRWEB) , ... July 06, 2015 , ... ... solutions, announced today that Randstad Technologies selected Aspect Software Unified IP contact center ... the United States, selected Aspect Unified IP as its future call center platform. ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:National Bone Health Screening and Awareness Day 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3
... Should men over a certain age be treated for prostate ... result in significant side effects if they may not live ... UCLA,s Jonsson Comprehensive Cancer Center has shown that men over ... a single comorbid condition such as peripheral vascular disease or ...
... (HealthDay News) -- Diabetes patients who visit a primary ... their blood glucose, blood pressure and cholesterol levels, researchers ... risk of diabetes-related complications, but most diabetes patients do ... do not outline how often diabetes patients should see ...
... Sept. 26, 2011 A large-scale data review ... over the last decade showed the endoscopic procedure to ... the small intestine. DBE had a pooled detection rate ... mid-gastrointestinal bleeding was found to be the most common ...
... patients who use a new combination of the chemotherapy, ... before surgery have an 88 percent chance of surviving ... trial presented at the plenary session, October 3, 2011, ... for Radiation Oncology (ASTRO). "The results of the ...
... Tampa, Fla. (Sept, 26 2011) Researchers in Japan have ... canine teeth and dental pulp can be grafted and produce ... in the current issue of Cell Transplantation ... defects can occur for a number of reasons, and autogenous ...
... 26 (HealthDay News) -- Heart attack patients who take ... drugs such as aspirin or Plavix have a higher ... only, a new study finds. Commonly prescribed SSRIs ... prevent blood cells from sticking together and forming a ...
Cached Medicine News:Health News:Elderly patients may be undertreated for prostate cancer 2Health News:Elderly patients may be undertreated for prostate cancer 3Health News:More Frequent Doctor Visits May Benefit Diabetes Patients 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 2Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 3Health News:Study examining large-scale data of double balloon enteroscopy shows it is safe and effective 4Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells 2Health News:Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients 2
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: